Evaluation of immune system in patients with transfusion-dependent beta-thalassemia in Rasoul-e-Akram Hospital in 2021: A descriptive cross-sectional study.
cellular immunity
humoral immunity
iron chelators agents
phagocytosis
thalassemia major
Journal
Health science reports
ISSN: 2398-8835
Titre abrégé: Health Sci Rep
Pays: United States
ID NLM: 101728855
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
13
06
2022
revised:
13
09
2022
accepted:
15
09
2022
entrez:
10
10
2022
pubmed:
11
10
2022
medline:
11
10
2022
Statut:
epublish
Résumé
Thalassemia syndromes are the most common hemoglobinopathy globally related to blood transfusion and iron overload in the body. Splenectomy, excessive iron overload, and repeated exposure to antigens in blood transfusions can cause severe damage to the patient's immune system making the patient prone to frequent infection. This study evaluates the immune system status and infection rate in beta-thalassemia major patients receiving iron chelators. This descriptive cross-sectional study was performed in Rasoul-e-Akram Hospital on patients with a beta-thalassemia major who had iron overload due to frequent blood transfusions. The percentage of lymphocyte markers was determined by flow cytometry. Serum levels of immunoglobin were measured by nephelometric assay. Also, Nitro blue tetrazolium and dihydrorhodamine assays were used to evaluate the phagocytic function. Of the 106 patients participating in this study, 59 (55.7%) and 47 (44.3%) are male and female, respectively. The mean age ± SD of participants was 24.7 ± 12.1 years with 4 to 55 years. There was no significant correlation between sex, the C3 and C4 complements, the lymphocyte markers, and the immunoglobulin levels. Furthermore, all of these variables increased significantly over 30 ( Iron chelator agents effectively improve patients' immune system with thalassemia major. The increase in IgG and IgM immunoglobulins levels is due to frequent blood transfusions, which stimulate the immune system.
Sections du résumé
Background and aims
UNASSIGNED
Thalassemia syndromes are the most common hemoglobinopathy globally related to blood transfusion and iron overload in the body. Splenectomy, excessive iron overload, and repeated exposure to antigens in blood transfusions can cause severe damage to the patient's immune system making the patient prone to frequent infection. This study evaluates the immune system status and infection rate in beta-thalassemia major patients receiving iron chelators.
Methods
UNASSIGNED
This descriptive cross-sectional study was performed in Rasoul-e-Akram Hospital on patients with a beta-thalassemia major who had iron overload due to frequent blood transfusions. The percentage of lymphocyte markers was determined by flow cytometry. Serum levels of immunoglobin were measured by nephelometric assay. Also, Nitro blue tetrazolium and dihydrorhodamine assays were used to evaluate the phagocytic function.
Results
UNASSIGNED
Of the 106 patients participating in this study, 59 (55.7%) and 47 (44.3%) are male and female, respectively. The mean age ± SD of participants was 24.7 ± 12.1 years with 4 to 55 years. There was no significant correlation between sex, the C3 and C4 complements, the lymphocyte markers, and the immunoglobulin levels. Furthermore, all of these variables increased significantly over 30 (
Conclusion
UNASSIGNED
Iron chelator agents effectively improve patients' immune system with thalassemia major. The increase in IgG and IgM immunoglobulins levels is due to frequent blood transfusions, which stimulate the immune system.
Identifiants
pubmed: 36210881
doi: 10.1002/hsr2.871
pii: HSR2871
pmc: PMC9528955
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e871Informations de copyright
© 2022 The Authors. Health Science Reports published by Wiley Periodicals LLC.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Natl Med Assoc. 1997 Nov;89(11):753-7
pubmed: 9375480
Medicina (B Aires). 1989;49(2):131-4
pubmed: 2640481
Haematologica. 2004 Oct;89(10):1187-93
pubmed: 15477202
Mediterr J Hematol Infect Dis. 2009 Dec 28;1(1):e2009028
pubmed: 21415996
Hemoglobin. 2010;34(1):95-106
pubmed: 20113293
Indian J Pediatr. 1997 Mar-Apr;64(2):215-9
pubmed: 10771839
Am J Pediatr Hematol Oncol. 1984 Winter;6(4):371-8
pubmed: 6241995
Maedica (Bucur). 2013 Sep;8(4):328-32
pubmed: 24790662
Ann Hematol. 2009 Jan;88(1):21-7
pubmed: 18690440
Clin Exp Immunol. 1987 Jun;68(3):621-9
pubmed: 3498580
Eur J Haematol. 2004 Nov;73(5):359-66
pubmed: 15458515
Acta Haematol. 1990;83(2):76-81
pubmed: 2106199
Am J Hematol. 1990 Sep;35(1):13-7
pubmed: 2389765
N Am J Med Sci. 2012 Mar;4(3):145-6
pubmed: 22454829
Indian J Pediatr. 2000 Dec;67(12):871-6
pubmed: 11262984
Best Pract Res Clin Obstet Gynaecol. 2017 Feb;39:3-15
pubmed: 27876354
Acta Med Indones. 2014 Jul;46(3):217-25
pubmed: 25348184
Br J Haematol. 1993 Sep;85(1):153-8
pubmed: 8251384
Haematologica. 2010 Mar;95(3):345-8
pubmed: 20207838
Br J Haematol. 1980 Jul;45(3):405-16
pubmed: 6968582
J Lab Clin Med. 1999 Apr;133(4):353-61
pubmed: 10218766
J Pediatr Hematol Oncol. 2000 Nov-Dec;22(6):581-7
pubmed: 11132234
Boll Ist Sieroter Milan. 1983;62(6):524-30
pubmed: 6677264
Ann Clin Lab Sci. 2000 Oct;30(4):354-65
pubmed: 11045759
Pediatr Blood Cancer. 2007 May;48(5):550-4
pubmed: 16972241
J Paediatr Child Health. 2011 Aug;47(8):535-40
pubmed: 21392144
Haematologica. 1994 Sep-Oct;79(5):406-12
pubmed: 7843626
Indian Pediatr. 1993 Jul;30(7):893-6
pubmed: 8132281
Br J Haematol. 1993 Dec;85(4):773-7
pubmed: 7918042
J Coll Physicians Surg Pak. 2014 Jul;24(7):467-71
pubmed: 25052967